Akari Therapeutics (AKTX) Stock: Why It's Up Today
Updated Oct 19, 2026, 4:00 PM ET · closing price
AKTX jumps 20.9% to $9.89. Closed at $9.89, +20.90% vs the prior close of $8.18. Day range $8.52–$10.00, opened at $9.01.
AKTX daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — AKTX jumps 20.9% to $9.89
- Closed at $9.89, +20.90% vs the prior close of $8.18. Day range $8.52–$10.00, opened at $9.01.
- Volume was 78.16K shares, 1.1x its 50-day average of 69.68K.
- Price is +8.4% vs its 50-day average ($9.13) and +7.6% vs its 200-day average ($9.19).
- 52-week range $3.02–$33.60; today's close sits at 22% of that range, 70.6% below the 52-week high.
Oct 16, 2026 — AKTX slides 7.5% to $8.18
- Closed at $8.18, -7.47% vs the prior close of $8.84. Day range $8.02–$8.66, opened at $8.30.
- Volume was 21.62K shares, 0.3x its 50-day average of 69.46K — lighter than usual.
- Price is -9.8% vs its 50-day average ($9.07) and -11.1% vs its 200-day average ($9.20).
- 52-week range $3.02–$33.60; today's close sits at 17% of that range, 75.7% below the 52-week high.
Oct 15, 2026 — AKTX jumps 21.4% to $8.84
- Closed at $8.84, +21.43% vs the prior close of $7.28. Day range $7.00–$8.89, opened at $7.87.
- Volume was 55.70K shares, 0.8x its 50-day average of 68.79K.
- Price is -2.5% vs its 50-day average ($9.07) and -4.0% vs its 200-day average ($9.21).
- 52-week range $3.02–$36.76; today's close sits at 17% of that range, 76.0% below the 52-week high.
Oct 14, 2026 — AKTX slides 7.8% to $7.28, a 1-month low, 3 down days in a row
- Closed at $7.28, -7.85% vs the prior close of $7.90. Day range $7.19–$8.10, opened at $8.10.
- Volume was 34.90K shares, 0.5x its 50-day average of 68.26K — lighter than usual.
- Price is -19.5% vs its 50-day average ($9.04) and -21.0% vs its 200-day average ($9.22).
- 52-week range $3.02–$39.64; today's close sits at 12% of that range, 81.6% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — AKTX slides 7.5% to $7.90, a 1-month low
- Closed at $7.90, -7.49% vs the prior close of $8.54. Day range $7.90–$8.70, opened at $8.33.
- Volume was 18.50K shares, 0.3x its 50-day average of 68.37K — lighter than usual.
- Price is -12.7% vs its 50-day average ($9.05) and -14.5% vs its 200-day average ($9.24).
- 52-week range $3.02–$39.64; today's close sits at 13% of that range, 80.1% below the 52-week high.
Oct 12, 2026 — AKTX dips 2.6% to $8.54
- Closed at $8.54, -2.62% vs the prior close of $8.77. Day range $8.34–$9.05, opened at $8.70.
- Volume was 112.40K shares, 1.7x its 50-day average of 66.42K.
- Price is -5.5% vs its 50-day average ($9.04) and -7.7% vs its 200-day average ($9.25).
- 52-week range $3.02–$40.00; today's close sits at 15% of that range, 78.7% below the 52-week high.
Oct 9, 2026 — AKTX jumps 7.9% to $8.77
- Closed at $8.77, +7.87% vs the prior close of $8.13. Day range $8.20–$8.97, opened at $8.51.
- Volume was 76.40K shares, 1.2x its 50-day average of 66.27K.
- Price is -2.8% vs its 50-day average ($9.02) and -5.3% vs its 200-day average ($9.26).
- 52-week range $3.02–$42.80; today's close sits at 14% of that range, 79.5% below the 52-week high.
Oct 8, 2026 — AKTX slides 5.7% to $8.13, a 1-month low
- Closed at $8.13, -5.74% vs the prior close of $8.62. Day range $8.13–$8.73, opened at $8.61.
- Volume was 61.90K shares, 1.0x its 50-day average of 65.10K.
- Price is -9.8% vs its 50-day average ($9.01) and -12.3% vs its 200-day average ($9.27).
- 52-week range $3.02–$44.00; today's close sits at 12% of that range, 81.5% below the 52-week high.
Oct 7, 2026 — AKTX rises 2.8% to $8.62
- Closed at $8.62, +2.80% vs the prior close of $8.39. Day range $8.05–$8.62, opened at $8.46.
- Volume was 32.40K shares, 0.5x its 50-day average of 65.04K — lighter than usual.
- Price is -4.3% vs its 50-day average ($9.01) and -7.0% vs its 200-day average ($9.28).
- 52-week range $3.02–$44.20; today's close sits at 14% of that range, 80.5% below the 52-week high.
Oct 6, 2026 — AKTX slides 6.2% to $8.39, a 1-month low
- Closed at $8.39, -6.15% vs the prior close of $8.94. Day range $8.13–$8.96, opened at $8.96.
- Volume was 19.80K shares, 0.3x its 50-day average of 65.70K — lighter than usual.
- Price is -6.9% vs its 50-day average ($9.01) and -9.6% vs its 200-day average ($9.28).
- 52-week range $3.02–$44.20; today's close sits at 13% of that range, 81.0% below the 52-week high.
Oct 5, 2026 — AKTX rises 2.5% to $8.94
- Closed at $8.94, +2.52% vs the prior close of $8.72. Day range $8.53–$9.39, opened at $8.84.
- Volume was 9.60K shares, 0.1x its 50-day average of 66.07K — lighter than usual.
- Price is -0.8% vs its 50-day average ($9.01) and -3.8% vs its 200-day average ($9.29).
- 52-week range $3.02–$44.20; today's close sits at 14% of that range, 79.8% below the 52-week high.
Oct 2, 2026 — AKTX dips 1.4% to $8.72, a 1-month low, 4 down days in a row
- Closed at $8.72, -1.36% vs the prior close of $8.84. Day range $8.26–$9.14, opened at $9.01.
- Volume was 15.30K shares, 0.2x its 50-day average of 66.10K — lighter than usual.
- Price is -3.2% vs its 50-day average ($9.00) and -6.2% vs its 200-day average ($9.30).
- 52-week range $3.02–$44.20; today's close sits at 14% of that range, 80.3% below the 52-week high.
- That makes 4 straight losses.
AKTX bull case vs bear case (from the data)
- Price is +8.4% vs its 50-day average — short-term trend is up.
- Price is +7.6% vs its 200-day average — above the long-term trend line.
- Latest fiscal-year net income: loss of $17.30M.
- Share count up 138.8% in a year (dilution).
- High volatility: average daily move of 6.2% over 20 sessions.
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
AKTX latest news & SEC filings
Every SEC filing by or about AKTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Prudo-Chlebosz Raymond received an award of 9,072 shares at $7.90 (≈$71.66K) on Aug 18, 2026; now holds 73,621
- Prudo-Chlebosz Raymond received an award of 3,240 shares at $7.90 (≈$25.59K) on Oct 5, 2026; now holds 76,861
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Huh Hoyoung received an award of 17,249 shares at $7.90 (≈$136.25K) on Aug 18, 2026; now holds 134,645
- Huh Hoyoung received an award of 6,160 shares at $7.90 (≈$48.66K) on Oct 5, 2026; now holds 140,805
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Patel Sandip I received an award of 12,100 shares at $7.90 (≈$95.58K) on Aug 18, 2026; now holds 24,512
- Patel Sandip I received an award of 4,313 shares at $7.90 (≈$34.07K) on Oct 5, 2026; now holds 28,825
- Patel Sandip I converted options/RSUs into 3,866 shares at $0.00 (≈$2) on Oct 14, 2026; now holds 32,691
- Patel Sandip I converted options/RSUs into 6,186 shares at $0.00 (≈$2) on Oct 14, 2026; now holds 38,877
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Bazemore Robert B received an award of 13,100 shares at $7.90 (≈$103.48K) on Aug 18, 2026; now holds 14,216
- Bazemore Robert B received an award of 4,677 shares at $7.90 (≈$36.94K) on Oct 5, 2026; now holds 18,893
- Bazemore Robert B converted options/RSUs into 773 shares at $0.00 (≈$0) on Oct 14, 2026; now holds 19,666
- Bazemore Robert B converted options/RSUs into 3,093 shares at $0.00 (≈$1) on Oct 14, 2026; now holds 22,759
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gaslightwala Abizer converted options/RSUs into 19,333 shares at $0.00 (≈$8) on Oct 14, 2026; now holds 33,440
- Gaslightwala Abizer converted options/RSUs into 7,733 shares at $0.00 (≈$3) on Oct 14, 2026; now holds 41,173
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Patel Samir Rashmikant received an award of 6,300 shares at $7.90 (≈$49.76K) on Aug 18, 2026; now holds 9,866
- Patel Samir Rashmikant received an award of 2,236 shares at $7.90 (≈$17.66K) on Oct 5, 2026; now holds 12,102
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$4.81M (prior year -$1.90M) (loss widened vs Jun 30, 2025)
- Diluted EPS: $0.00 (prior year $0.00)
Aug 12, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 13, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Things to know before you trade AKTX
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 15, 2025, Apr 16, 2025, Aug 19, 2024. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 6.16% (largest 21.4%). That is a volatile stock.
- Liquidity: about 51.44K shares (≈$508.77K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $9.89 vs a range of $3.02–$33.60 (22% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:40 on Mar 31, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 1, 2026; 8-K Aug 13, 2026; 10-Q Aug 13, 2026.
- Share count: 155.76B shares outstanding (Aug 13, 2026), +138.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
AKTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 9.01 | 10.00 | 8.52 | 9.89 | 78.16K |
| Oct 16, 2026 | 8.72 | 8.72 | 8.02 | 8.18 | 21.70K |
| Oct 15, 2026 | 7.87 | 8.89 | 7.00 | 8.84 | 55.70K |
| Oct 14, 2026 | 8.10 | 8.10 | 7.19 | 7.28 | 34.90K |
| Oct 13, 2026 | 8.33 | 8.70 | 7.90 | 7.90 | 18.50K |
| Oct 12, 2026 | 8.70 | 9.05 | 8.34 | 8.54 | 112.40K |
| Oct 9, 2026 | 8.51 | 8.97 | 8.20 | 8.77 | 76.40K |
| Oct 8, 2026 | 8.61 | 8.73 | 8.13 | 8.13 | 61.90K |
| Oct 7, 2026 | 8.46 | 8.62 | 8.05 | 8.62 | 32.40K |
| Oct 6, 2026 | 8.96 | 8.96 | 8.13 | 8.39 | 19.80K |
| Oct 5, 2026 | 8.84 | 9.39 | 8.53 | 8.94 | 9.60K |
| Oct 2, 2026 | 9.01 | 9.14 | 8.26 | 8.72 | 15.30K |
| Oct 1, 2026 | 9.35 | 10.00 | 8.55 | 8.84 | 28.60K |
| Sep 30, 2026 | 9.58 | 10.05 | 8.80 | 9.30 | 47.00K |
| Sep 29, 2026 | 9.83 | 10.75 | 9.55 | 9.72 | 50.70K |
| Sep 28, 2026 | 9.99 | 10.98 | 9.69 | 9.81 | 82.00K |
| Sep 25, 2026 | 10.25 | 10.25 | 9.30 | 9.76 | 71.50K |
| Sep 24, 2026 | 9.90 | 10.10 | 9.56 | 10.06 | 47.40K |
| Sep 23, 2026 | 10.42 | 10.42 | 9.32 | 9.66 | 86.40K |
| Sep 22, 2026 | 9.24 | 10.10 | 8.53 | 10.05 | 78.50K |
About Akari Therapeutics
Akari Therapeutics (AKTX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in TAMPA, FL. State of incorporation: United Kingdom. Fiscal year ends December 31. SEC CIK 1541157.
AKTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Robert B Bazemore | Director | Dec 18, 2025 |
| Abizer Gaslightwala | CEO | Jun 25, 2026 |
| Hoyoung Huh | Director | Dec 18, 2025 |
| James R Neal | Director | Mar 16, 2026 |
| Samir Rashmikant Patel | Director | Jul 17, 2026 |
| Sandip I Patel | Director | Dec 18, 2025 |
| Raymond Prudo-Chlebosz | Director | Dec 18, 2025 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Kameel D. Farag | Interim CFO | Aug 19, 2026 |
| Abizer Gaslightwala | CEO | Jun 25, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
AKTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-17.30M | 0.00 | $-10.57M |
| Dec 31, 2024 | — | $-19.79M | 0.00 | $-12.55M |
| Dec 31, 2023 | — | $-10.01M | 0.00 | $-16.43M |
| Dec 31, 2022 | — | $-17.75M | 0.00 | $-21.50M |
| Dec 31, 2015 | — | $-45.32M | — | $-4.97M |
Latest balance sheet: total assets $38.62M, total liabilities $20.03M, cash $7.69M (as of Jun 30, 2026).
AKTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $7.00 |
| May 15, 2025 | 8-K Item 2.02 (results) | $52.80 |
| Apr 16, 2025 | 8-K Item 2.02 (results) | $44.00 |
| Aug 19, 2024 | 8-K Item 2.02 (results) | — |
| May 16, 2024 | 8-K Item 2.02 (results) | — |
| Apr 1, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Tesla (TSLA)Space Exploration Technologies (SPCX)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on AKTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 19, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.